Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to fight rare cancer

NCT ID NCT05747729

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial tests whether adding two drugs—surufatinib and serplulimab—to standard chemotherapy can help people with neuroendocrine carcinoma, a rare and aggressive cancer. The study enrolls adults who have not had prior treatment and measures how long the cancer stays under control. It is an early-phase study at one hospital, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
surufatinib and serplulimab combined with platinum/etoposide chemotherapy
What this could lead to
If successful, this combination could offer a new first-line treatment option for neuroendocrine carcinoma, potentially improving how long patients live without their cancer worsening.
What could go wrong
This is an early-phase, single-center trial with only 60 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to improve outcomes over standard therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE; CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.